# Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc. is an Asset Manager based in South San Francisco, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** South San Francisco, United States
- **Region:** North America
- **Address:** South San Francisco, California, United States
- **Founded:** 2016
- **Assets under management:** Undisclosed
- **Website:** sentibio.com

## Regulatory record

- **Reports private funds:** No

## About

Senti Biosciences was launched in 2016 by Timothy Lu and Philip Lee, both synthetic-biology researchers from MIT and Harvard. The company's core technology — gene circuits that enable cells to sense, compute, and respond to disease microenvironments — emerged from academic work published in journals such as Nature Biotechnology (2016). Wealth origin for the founding team is not publicly disclosed, and the firm is structured as a publicly traded biotechnology company, not a family office or traditional asset manager. The firm's strategy centers on engineering logic-gated CAR-NK and CAR-T cells for oncology, targeting solid tumors through what it calls a "sense-and-respond" approach. Its lead program, SENTI-202, is in Phase 1 clinical trials for acute myeloid leukemia (AML), disclosed in a November 2024 update. Other preclinical assets address hepatocellular carcinoma (SENTI-301A) and ovarian cancer. Senti went public in February 2022 via a SPAC merger with Dynamics Special Purpose Corp., raising gross proceeds of approximately $196 million (per the firm's SEC filings). The company is headquartered in South San Francisco, with no disclosed additional offices. As of May 2026, Senti Biosciences has not disclosed total professionals count or AUM. No philanthropic foundation or adjacent investment vehicle has been named. This computational-biology approach — rooted in synthetic biology rather than traditional pharmacology — creates a proprietary moat around how the cells are programmed, not just what they target.

## Sectors

- Biotechnology
- Therapeutics
- Gene Editing
- Cell Therapy

## People

- Timothy Lu — CEO and Co-founder
- Philip Lee — President and Co-founder
- Jim McKnight — Chief Business Officer

## Questions

### How does Senti Biosciences source its therapeutic pipeline?

Senti's pipeline originates from its proprietary gene-circuit platform, which programs cells to respond to disease-specific combinations of signals. The firm identifies new targets and circuit designs through internal research and collaborations, such as a 2018 partnership with Celgene that provided up to $100 million in milestones (per SEC filings). Academic contributions from the labs of co-founders Lu and Lee at MIT and Harvard also feed the pipeline.

### Does Senti Biosciences participate in fund commitments or only direct therapeutic development?

Senti Biosciences engages exclusively in direct therapeutic development and does not commit capital to external funds. The firm's capital is deployed into R&D, clinical trials, and platform expansion. It has not disclosed any alternative investment activity such as venture funds, hedge funds, or private credit.

### What therapeutic areas does Senti Biosciences target?

Senti Biosciences focuses on oncology, specifically solid tumors and hematologic malignancies. Its lead program, SENTI-202, targets acute myeloid leukemia (AML). Preclinical programs address hepatocellular carcinoma (SENTI-301A) and ovarian cancer. The firm's gene-circuit platform is designed to be adaptable to other disease areas, but no public disclosures exist beyond oncology.

### How is Senti Biosciences funded?

Senti Biosciences was initially funded through venture capital, including a $38 million Series A in 2018 led by 8VC and Celgene (per the firm's press releases, 2018). It went public in February 2022 via a SPAC merger that raised approximately $196 million in gross proceeds (per SEC filings). No additional funding rounds or debt facilities have been publicly disclosed since the SPAC close.

## Related profiles

- [Holistic Asset Finance Group Co., Ltd.](https://altss.com/profile/holistic-asset-finance-group-co-ltd)
- [GIFTIFY, INC.](https://altss.com/profile/giftify-inc)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/senti-biosciences-holdings-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology